Treatment of xenografted human CRC on the CAM with anti-vimentin antibodies inhibited both tumor growth and vascular density in the tumors (Fig. 3g, h), and resulted in increased necrosis (Supplementary Fig. 4a). Here, VIM is linked to neoplasm.